TY - JOUR
T1 - Carbon ion radiotherapy in the management of non-small cell lung cancer
AU - Seneviratne, Danushka
AU - Ishikawa, Hitoshi
AU - Mao, Jingfang
AU - Dougherty, Jingjing M.
AU - Bush, Aaron
AU - Thomas, Mathew
AU - Manochakian, Rami
AU - Lou, Yanyan
AU - Owen, Dawn
AU - Sio, Terence T.
AU - Kirwan, Jessica
AU - Ko, Stephen J.
AU - Hoppe, Bradford S.
N1 - Publisher Copyright:
© 2022 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.
PY - 2022/3
Y1 - 2022/3
N2 - Despite advancements in local-regional and systemic therapies, non-small cell cancer (NSCLC) remains a leading cause of death worldwide. Among those treated with standard-of-care modalities, 30–60% experience disease recurrence. Carbon ion radiotherapy (CIRT) is a form of densely ionizing radiotherapy with unique physical and biological advantages over traditional photon and proton modalities. CIRT is expected to have a superior biological impact on tumors, and is believed to be less impacted by the presence of tumor hypoxia or cell cycle state. It also shows highly conformal physical dose deposition due to reduced lateral scattering of the particles, limiting the radiation dose delivered to adjacent organs at risk. To implement CIRT as a viable option in the treatment of NSCLC, technical aspects of treatment delivery – including appropriate beam arrangements, dose calculation algorithms, radiobiological models, and methods of motion management – must be thoroughly investigated. Furthermore, randomized clinical trials comparing CIRT versus traditional radiation modalities must be performed to show the benefits and risks associated with this novel treatment modality. This review discusses the rationale for utilizing CIRT in NSCLC, available clinical data to date, and the potential for future investigations that may pave the path for improving outcomes in those diagnosed with NSCLC.
AB - Despite advancements in local-regional and systemic therapies, non-small cell cancer (NSCLC) remains a leading cause of death worldwide. Among those treated with standard-of-care modalities, 30–60% experience disease recurrence. Carbon ion radiotherapy (CIRT) is a form of densely ionizing radiotherapy with unique physical and biological advantages over traditional photon and proton modalities. CIRT is expected to have a superior biological impact on tumors, and is believed to be less impacted by the presence of tumor hypoxia or cell cycle state. It also shows highly conformal physical dose deposition due to reduced lateral scattering of the particles, limiting the radiation dose delivered to adjacent organs at risk. To implement CIRT as a viable option in the treatment of NSCLC, technical aspects of treatment delivery – including appropriate beam arrangements, dose calculation algorithms, radiobiological models, and methods of motion management – must be thoroughly investigated. Furthermore, randomized clinical trials comparing CIRT versus traditional radiation modalities must be performed to show the benefits and risks associated with this novel treatment modality. This review discusses the rationale for utilizing CIRT in NSCLC, available clinical data to date, and the potential for future investigations that may pave the path for improving outcomes in those diagnosed with NSCLC.
KW - carbon ion
KW - high-linear energy transfer
KW - non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85126731446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126731446&partnerID=8YFLogxK
U2 - 10.1002/pro6.1146
DO - 10.1002/pro6.1146
M3 - Review article
AN - SCOPUS:85126731446
SN - 2398-7324
VL - 6
SP - 69
EP - 74
JO - Precision Radiation Oncology
JF - Precision Radiation Oncology
IS - 1
ER -